

Pierpaolo Alongi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6413684/publications.pdf>

Version: 2024-02-01

85
papers

1,331
citations

361413

20
h-index

414414

32
g-index

90
all docs

90
docs citations

90
times ranked

2082
citing authors

#	ARTICLE	IF	CITATIONS
1	Imaging features of adrenal masses. Insights Into Imaging, 2019, 10, 1.	3.4	120
2	Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 464-473.	6.4	79
3	Radiomics analysis of 18F-Choline PET/CT in the prediction of disease outcome in high-risk prostate cancer: an explorative study on machine learning feature classification in 94 patients. European Radiology, 2021, 31, 4595-4605.	4.5	54
4	18F-FDG PET reveals unique features of large vessel inflammation in patients with Takayasu's arteritis. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1109-1118.	6.4	53
5	A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting. Journal of Alzheimer's Disease, 2017, 59, 603-614.	2.6	48
6	Predictive value of 18F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 404-413.	6.4	47
7	18F-Fluoroethylcholine (18F-Cho) PET/MRI Functional Parameters in Pediatric Astrocytic Brain Tumors. Clinical Nuclear Medicine, 2015, 40, e40-e45.	1.3	41
8	Evaluation of an optimized [¹⁸ F]fluoro- β -deoxyglucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders. European Journal of Neurology, 2017, 24, 687.	3.3	40
9	Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 224-233.	6.4	39
10	Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is ¹¹ C-Choline PET/CT Predictive of Survival Outcomes?. Journal of Nuclear Medicine, 2015, 56, 1836-1842.	5.0	35
11	Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC). European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1837-1848.	6.4	35
12	Neuropsychological and FDG-PET profiles in VGKC autoimmune limbic encephalitis. Brain and Cognition, 2016, 108, 81-87.	1.8	34
13	18F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 1348.	3.7	34
14	Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis. Scandinavian Journal of Clinical and Laboratory Investigation, 2020, 80, 313-317.	1.2	30
15	The role of PET/CT in the evaluation of patients affected by limbic encephalitis: A systematic review of the literature. Journal of Neuroimmunology, 2015, 284, 44-48.	2.3	29
16	Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis. Diagnostics, 2020, 10, 598.	2.6	28
17	Inflammatory Pseudotumor of Mediastinum Treated with Tomotherapy and Monitored with FDG-PET/CT: Case Report and Literature Review. Tumori, 2010, 96, 322-326.	1.1	25
18	Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience. Hellenic Journal of Nuclear Medicine, 2015, 18, 97-102.	0.3	24

#	ARTICLE	IF	CITATIONS
19	Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. <i>Radiologia Medica</i> , 2018, 123, 719-725.	7.7	22
20	Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now. <i>European Radiology</i> , 2018, 28, 1187-1193.	4.5	22
21	Feasibility on the Use of Radiomics Features of 11[C]-MET PET/CT in Central Nervous System Tumours: Preliminary Results on Potential Grading Discrimination Using a Machine Learning Model. <i>Current Oncology</i> , 2021, 28, 5318-5331.	2.2	21
22	PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature. <i>Cancers</i> , 2022, 14, 1770.	3.7	21
23	Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 85-94.	6.4	20
24	Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 117-124.	4.4	20
25	18F-Florbetaben PET/CT to Assess Alzheimer's Disease: A new Analysis Method for Regional Amyloid Quantification. <i>Journal of Neuroimaging</i> , 2019, 29, 383-393.	2.0	19
26	Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 1. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 74-79.	4.4	18
27	Choline PET/CT features to predict survival outcome in high-risk prostate cancer restaging: a preliminary machine-learning radiomics study. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 66, .	0.7	18
28	[68Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [177Lu]DOTATOC PRRT: The "Theranomics" Concept. <i>Cancers</i> , 2022, 14, 984.	3.7	18
29	Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid. <i>Annals of Nuclear Medicine</i> , 2018, 32, 7-15.	2.2	17
30	18F-FDG PET/CT for Early Postradiotherapy Assessment in Solitary Bone Plasmacytomas. <i>Clinical Nuclear Medicine</i> , 2015, 40, e399-e404.	1.3	16
31	18F-Fluorodeoxyglucose-PET/CT in locally advanced head and neck cancer can influence the stage migration and nodal radiation treatment volumes. <i>Radiologia Medica</i> , 2017, 122, 952-959.	7.7	16
32	Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by ¹⁸ F-FDG-PET/CT. <i>British Journal of Radiology</i> , 2018, 91, 20180058.	2.2	16
33	Role of molecular imaging in the management of patients affected by inflammatory bowel disease: State-of-the-art. <i>World Journal of Radiology</i> , 2016, 8, 829.	1.1	16
34	PET Neuroimaging: Insights on Dystonia and Tourette Syndrome and Potential Applications. <i>Frontiers in Neurology</i> , 2014, 5, 183.	2.4	15
35	Artificial Neural Networks in Cardiovascular Diseases and its Potential for Clinical Application in Molecular Imaging. <i>Current Radiopharmaceuticals</i> , 2021, 14, 209-219.	0.8	15
36	Radiomics Analysis of Brain [18F]FDG PET/CT to Predict Alzheimer's Disease in Patients with Amyloid PET Positivity: A Preliminary Report on the Application of SPM Cortical Segmentation, Pyradiomics and Machine-Learning Analysis. <i>Diagnostics</i> , 2022, 12, 933.	2.6	15

#	ARTICLE	IF	CITATIONS
37	Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications. <i>Cancers</i> , 2019, 11, 1412.	3.7	14
38	The Role of PET in Supratentorial and Infratentorial Pediatric Brain Tumors. <i>Current Oncology</i> , 2021, 28, 2481-2495.	2.2	12
39	Multiparametric MRI and Radiomics in Prostate Cancer: A Review of the Current Literature. <i>Diagnostics</i> , 2021, 11, 1829.	2.6	12
40	Clinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancer. <i>Nuclear Medicine Communications</i> , 2018, 39, 741-746.	1.1	11
41	Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2871-2882.	6.4	11
42	Artificial Intelligence Applications on Restaging [18F]FDG PET/CT in Metastatic Colorectal Cancer: A Preliminary Report of Morpho-Functional Radiomics Classification for Prediction of Disease Outcome. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 2941.	2.5	11
43	[¹¹ C]choline-PET-guided Helical Tomotherapy and Estramustine in a Patient with Pelvic-Recurrent Prostate Cancer: Local Control and Toxicity Profile after 24 Months. <i>Tumori</i> , 2010, 96, 613-617.	1.1	9
44	Brain PET/CT using prostate cancer radiopharmaceutical agents in the evaluation of gliomas. <i>Clinical and Translational Imaging</i> , 2020, 8, 433-448.	2.1	9
45	Choline-PET/CT in the Differential Diagnosis Between Cystic Glioblastoma and Intraparenchymal Hemorrhage. <i>Current Radiopharmaceuticals</i> , 2019, 12, 88-92.	0.8	9
46	Radiotracers for Amyloid Imaging in Neurodegenerative Disease: State-of-the-Art and Novel Concepts. <i>Current Medicinal Chemistry</i> , 2018, 25, 3131-3140.	2.4	8
47	Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma. <i>Nuclear Medicine Communications</i> , 2019, 40, 808-814.	1.1	8
48	Megavoltage CT Images of Helical Tomotherapy Unit for Radiation Treatment Simulation: Impact on Feasibility of Treatment Planning in a Prostate Cancer Patient with Bilateral Femoral Prostheses. <i>Tumori</i> , 2011, 97, 221-224.	1.1	7
49	Clinical Impact of 18F-FDG PET/CT in the Diagnostic Workup of Pancreatic Ductal Adenocarcinoma: A Systematic Review. <i>Diagnostics</i> , 2020, 10, 1042.	2.6	7
50	Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2633-2638.	6.4	7
51	10-Year Clinical Experience With 18F-Choline PET/CT. <i>Clinical Nuclear Medicine</i> , 2020, 45, 594-603.	1.3	6
52	[11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months. <i>Tumori</i> , 2010, 96, 613-7.	1.1	6
53	The role of PET radiomic features in prostate cancer: a systematic review. <i>Clinical and Translational Imaging</i> , 2021, 9, 579-588.	2.1	5
54	Subcutaneous Uptake on [18F]Florbetaben PET/CT: a Case Report of Possible Amyloid-Beta Immune-Reactivity After COVID-19 Vaccination. <i>SN Comprehensive Clinical Medicine</i> , 2021, , 1-3.	0.6	5

#	ARTICLE	IF	CITATIONS
55	Megavoltage CT images of helical tomotherapy unit for radiation treatment simulation: impact on feasibility of treatment planning in a prostate cancer patient with bilateral femoral prostheses. <i>Tumori</i> , 2011, 97, 221-4.	1.1	5
56	Clinical and Prognostic Value of 18F-FDG-PET/CT in the Restaging Process of Recurrent Cutaneous Melanoma. <i>Current Radiopharmaceuticals</i> , 2020, 13, 42-47.	0.8	5
57	Potential clinical value of quantitative fluorine-18-fluorodeoxyglucose-PET/computed tomography using a graph-based method analysis in evaluation of incidental lesions of gastrointestinal tract. <i>Nuclear Medicine Communications</i> , 2019, 40, 1060-1065.	1.1	4
58	18F-FMISO PET imaging: insights over MRI in patients with glioma. <i>Clinical and Translational Imaging</i> , 2020, 8, 3-10.	2.1	4
59	PET/CT for the diagnostic assessment of patients with renal cancer. <i>Clinical and Translational Imaging</i> , 2018, 6, 207-216.	2.1	3
60	The role of 18F-Fluorodeoxyglucose PET/CT in restaging patients with small cell lung cancer: a systematic review. <i>Nuclear Medicine Communications</i> , 2021, 42, 839-845.	1.1	3
61	68Ga-dotatoc vs. 18F-FDG vs. radiolabelled PSMA PET/CT in renal cancer patients. <i>Annals of Translational Medicine</i> , 2019, 7, S150-S150.	1.7	3
62	FDG-PET/CT Predicts Outcome in Oropharyngeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes. <i>Current Radiopharmaceuticals</i> , 2017, 10, 102-110.	0.8	3
63	PET Evaluation of Late Cerebral Effect in Advanced Radiation Therapy Techniques for Cranial Base Tumors. <i>Current Radiopharmaceuticals</i> , 2018, 11, 86-91.	0.8	3
64	Prefrontal Cortical Stimulation in Tourette Disorder: Proof of a concept. <i>Clinical and Neuroimaging Study</i> . <i>Movement Disorders Clinical Practice</i> , 2018, 5, 499-505.	1.5	2
65	Focal Pancreatic Lesions: Role of Contrast-Enhanced Ultrasonography. <i>Diagnostics</i> , 2021, 11, 957.	2.6	2
66	Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 391-396.	1.0	2
67	[[18F]Fluorothymidine Positron Emission Tomography Imaging in Primary Brain Tumours: A Systematic Review. <i>Current Medical Imaging</i> , 2021, 17, .	0.8	2
68	PET/CT for the diagnostic assessment of patients with testicular cancer. <i>Clinical and Translational Imaging</i> , 2018, 6, 217-221.	2.1	1
69	The role of molecular imaging in the frame of the revised dementia with Lewy body criteria. <i>Clinical and Translational Imaging</i> , 2019, 7, 83-98.	2.1	1
70	Choline PET/CT and intraoperative management of primary brain tumors. New insights for contemporary neurosurgery. <i>Clinical and Translational Imaging</i> , 2020, 8, 401-404.	2.1	1
71	PET and SPECT Imaging in the SARS-CoV-2 Pandemic. <i>Current Radiopharmaceuticals</i> , 2020, 13, 87-88.	0.8	1
72	Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2021, 17, 807-815.	2.4	1

#	ARTICLE	IF	CITATIONS
73	PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1709-1711.	6.4	1
74	Amyloid PET in the diagnostic workup of neurodegenerative disease. Clinical and Translational Imaging, 2021, 9, 383-397.	2.1	1
75	AB0572â€¦Additional Role of FDG Pet/Ct in the Assessment of Disease Activity in Takayasu Arteritis. Annals of the Rheumatic Diseases, 2014, 73, 995.2-995.	0.9	0
76	Assessment of response to treatment in paediatric bone sarcomas by means of PET imaging. Clinical and Translational Imaging, 2016, 4, 41-55.	2.1	0
77	Reply to letter of Adams and Kwee: Critical considerations on the predictive value of end-of-treatment FDG/PET in lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 344-345.	6.4	0
78	Letter to the Editor Regarding â€œThe Radiological Imaging Features of Easily Misdiagnosed Epithelioid Glioblastoma in Seven Patientsâ€. World Neurosurgery, 2019, 125, 544-545.	1.3	0
79	Sentinel node identification with [99mTc]-tilmanocept SPECT/CT: a pictorial essay of clinical applications. Clinical and Translational Imaging, 2020, 8, 279-288.	2.1	0
80	Imaging in Melanoma Management: What's New Under the Sun?. Current Radiopharmaceuticals, 2020, 13, 3-5.	0.8	0
81	Molecular Imaging of Vulnerable Plaque. , 2021, , 73-107.		0
82	A xanthogranulomatous process resembling residual disease on endof- treatment 18f-FDG-PET/CT and Whole Body Magnetic Resonance performed on a primary breast lymphoma treated by ibrutinib plus rituximab-chop. Giornale Italiano Di Ostetricia E Ginecologia, 2016, 28, 390.	0.1	0
83	Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) sequentially treated with abiraterone acetate (AA) and radium-223 (RA223).. Journal of Clinical Oncology, 2020, 38, e17593-e17593.	1.6	0
84	Initial results of the use of a novel semiquantitative parameter in three-phase bone scan to predict 99mTc-HMPAO-labeled leukocyte scintigraphy in patients with unilateral total knee replacement. Nuclear Medicine Communications, 2021, 42, 198-204.	1.1	0
85	Advances in the In Vivo Quantitative and Qualitative Imaging Characterization of Gliomas. Cancers, 2022, 14, 3324.	3.7	0